Helocyte, Inc. (“Helocyte”), a portfolio company of Fortress Biotech, Inc., is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious disease (in particular, cytomegalovirus or “CMV”)

Press Releases

DATA FROM PHASE 1 TRIAL OF TRIPLEX VACCINE FOR CONTROL OF CYTOMEGALOVIRUS PUBLISHED IN BLOOD

FORTRESS BIOTECH (f/k/a Coronado Biosciences) FORMS NEW SUBSIDIARY, HELOCYTE, INC. (f/k/a DiaVax Biosciences) TO DEVELOP NOVEL IMMUNOTHERAPIES FOR CYTOMEGALOVIRUS

Pipeline